expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of the Company’s
fully repaid in November 2019 from the net proceeds of SHR’s IPO, an increase in income tax expense due to growth in transfer value of residential project as well as fair value adjustments on investment
regional or consolidated EBITDA. 4Core EBITDA is Reported EBITDA less Inventory gains/(losses) 5Core Net Profit is Reported Net Profit less Inventory gains/(losses) one-time extraordinary items 6Core EPS is
increase from expense of printing Baht 49.09 million or 94.33% comparing with same period of last year. The increase came from WPP in amount of Baht 43.37 million and Baht 11.59 million increase from
fixed interest rate from 2.05 to 3.01 percent per annum to reduce financial cost and risk management from floating interest rate. As a result, the Company has saved interest expense approximately by Baht
profit 596 33% 1,450 41% 143% 1,443 37% 3,738 42% 159% Other income 220 12% 87 2% -61% 402 10% 244 3% -39% Selling expense -217 -12% -450 -13% 107% -485 -12% -1,043 -12% 115% Administrative expense -367
435 (55) -12.6 Gains on sale of investments 181 499 (318) -63.7 Gain on reclassification of investment 3,409 2,496 (913) 36.6 Other income 327 43 284 660.5 Total revenues 20,404 19,088 1,316 6.9 Cost of
fixed cost from rental expense and administrative expense. However the 1st Consolidated Separate Amount Change Amount Change Q1.2019 Q1.2018 Amount % Q1.2019 Q1.2018 Amount % Revenue from sale – net
Interest income from the MRT Purple Line Project 97 110 (13) -11.8 Other income 68 8 60 750.0 Gains on sale of investments 106 245 (139) -56.7 Gain on reclassification of investment 3,409 - 3,409 N/A Total